Search bioRxiv⌕ Search

Biology subjects

Smallegan, M. J.

Publications and source records attributed to Smallegan, M. J..

5 recordsLinked to original sources

The accessible human surfaceome

Proteins associated with the extracellular face of the plasma membrane ("surface proteins" or the "surfaceome") are important therapeutic targets because they can direct therapeutics to specific cell types and deliver them into cells. However, experimental and computational databases disagree substantially on which proteins make up the human plasma membrane proteome, and none focus specifically on the set of accessible surface proteins that would be useful for therapeutic applications. Here, we used an agentic LLM pipeline to curate the accessible human surfaceome from literature. To assess performance, we built SurfaceBench, a manually curated benchmark of 147 proteins on which five reference databases frequently disagree. Our LLM triage agent classified surface status more accurately than existing databases and recovered 1,108 candidate surface proteins not present in any of them. On held-out clinical and viral-entry surface targets, the pipeline recovered 98-100% of established surface antigens. A literature-anchored deep-dive pipeline run on over 5,000 candidates then returned 1,783 canonical surface proteins and 1,252 with weaker or context-dependent surface evidence. Each queryable record contains 24 LLM-based annotation fields--including confidence, primary localization, and expression breadth--and seven deterministic structural and topological features. Unlike existing databases, our records trace every claim to the agent's reasoning and to exact quotes from the full-text literature it could access. All records can be browsed in an open-source viewer. These results show that LLMs reasoning over unstructured scientific text can build updatable, bespoke databases that outperform expert-curated resources, although performance remains limited by agent access to full-text literature.

bioinformatics↗

DNMT1 inhibition by pUG-fold quadruplex RNA

Aberrant DNA methylation is one of the earliest hallmarks of cancer. DNMT1 is responsible for methylating newly replicated DNA, but the precise regulation of DNMT1 to ensure faithful DNA methylation remains poorly understood. A link between RNA and chromatin-associated proteins has recently emerged, and several studies have shown that DNMT1 can be regulated by a variety of RNAs. In this study we have confirmed that human DNMT1 indeed interacts with multiple RNAs, including its own nuclear mRNA. Unexpectedly, we found that DNMT1 exhibits a strong and specific affinity for GU-rich RNAs that form a pUG-fold, a non-canonical G-quadruplex. We find that pUG-fold-capable RNAs inhibit DNMT1 activity by inhibiting binding of hemimethylated DNA, and additionally provide evidence for multiple RNA binding modes with DNMT1. Together, our data indicates that a human chromatin-associated protein binds to and is regulated by pUG-fold RNA.

biochemistry↗

The lncRNA Firre functions as a transcriptional activator from a distance

Numerous studies have now demonstrated that lncRNAs can influence gene expression programs leading to cell and organismal phenotypes. Typically, lncRNA perturbations and concomitant changes in gene expression are measured on the timescale of many hours to days. Thus, we currently lack a temporally grounded understanding of the primary, secondary, and tertiary relationships of lncRNA-mediated transcriptional and epigenetic regulation - despite being a prerequisite to elucidating lncRNA mechanisms. To begin to address when and where a lncRNA regulates gene expression, we genetically engineered cell lines to temporally induce the lncRNA Firre. Using this approach, we were able to monitor lncRNA transcriptional regulatory events from 15 min to four days. We observed that upon induction, Firre RNA regulates epigenetic and transcriptional states, in trans, within 30 min. These early regulatory events result in much larger transcriptional changes after twelve hours, well before current studies monitor lncRNA regulation. Moreover, Firre-mediated gene expression changes are epigenetically remembered for days. Overall, this study suggests that lncRNAs can rapidly regulate gene expression by establishing persistent epigenetic and transcriptional states.

genomics↗

Myosin 7b is a regulatory long noncoding RNA (lncMYH7b) in the human heart

Myosin heavy chain 7b (MYH7b) is an ancient member of the myosin heavy chain motor protein family that is expressed in striated muscles. In mammalian cardiac muscle, MYH7b RNA is expressed along with two other myosin heavy chains, {beta}-myosin heavy chain ({beta}-MyHC) and -myosin heavy chain (a-MyHC). However, unlike {beta}-MyHC and -MyHC which are maintained in a careful balance at the protein level, the MYH7b locus does not produce protein in the heart due to a post-transcriptional exon-skipping mechanism that occurs in a tissue specific manner. Whether this locus has a role in the heart beyond producing its intronic microRNA, miR-499, was unclear. Using cardiomyocytes derived from human induced pluripotent stem cells as a model system, we have found that the non-coding exon skipped RNA (lncMYH7b) affects the transcriptional landscape of the human heart, independent of miR-499. Specifically, lncMYH7b regulates the ratio of {beta}-MyHC to -MyHC, which is crucial for heart function. This regulation is likely achieved through control of members of the TEA domain transcription factor family (TEAD1 and TEAD3). Therefore, we conclude that this ancient gene has been repurposed by alternative splicing to produce a regulatory long-noncoding RNA in the human heart that affects the myosin composition of the heart.

molecular biology↗

Quantifying dynamic protein acetylation using quantitative stoichiometry

Protein acetylation is a widespread post-translational modification implicated in many cellular processes. Recent advances in mass spectrometry have enabled the cataloging of thousands of sites throughout the cell, however identifying regulatory acetylation marks have proven to be a daunting task. Knowledge of the kinetics and stoichiometry of site-specific acetylation are important factors to uncover function. Here, an improved method of quantifying acetylation stoichiometry was developed and validated, providing a detailed landscape of dynamic acetylation stoichiometry within cellular compartments. The dynamic nature of site-specific acetylation in response to serum stimulation was revealed. In two distinct human cell lines, growth factor stimulation led to site-specific, temporal acetylation changes, revealing diverse kinetic profiles that clustered into several groups. Overlap of dynamic acetylation sites among two different human cell lines suggested similar regulatory control points across major cellular pathways that include splicing, translation, and protein homeostasis. Rapid increases in acetylation on protein translational machinery suggest a positive regulatory role under pro-growth conditions. Lastly, higher median stoichiometry was observed in cellular compartments where active acetyltransferases are well-described.

biochemistry↗